MaxCyte (MXCT) (MXCT)
:MXCT
Want to see MXCT full AI Analyst Report?
MXCT Stock Chart & Stats
$0.84
-$0.03(-3.21%)
―
--
Day’s Range― - ―
52-Week Range$0.64 - $2.47
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$90.12M
Enterprise Value$87.99M
Total Cash (Recent Filing)$103.04M
Total Debt (Recent Filing)$17.94M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
May 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding106,861,430
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit3.90
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$4.50Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$30.84M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsMaxCyte’s consistently high gross margins (around 78–90% historically) indicate strong unit economics for instruments, consumables and services. Durable margin strength supports pricing power and provides a cushion to invest in R&D and absorb fixed cost reductions while revenue recovers.
Strong Balance Sheet And Lower Cash BurnLarge cash reserves with no debt and materially lower annual cash burn provide runway and strategic optionality. This durable financial flexibility permits funding new product rollouts, supporting partners through clinical inflection points and avoiding near‑term dilution while executing commercialization plans.
Installed Base Growth, New Product & SPL PipelineAn expanding installed base increases recurring consumables/service demand; the ExPERT DTX broadens product addressable market and drives incremental instrument/PA sales; a deep SPL pipeline with sizable milestone/royalty upside creates durable, non-linear revenue optionality as partnered programs advance.
Bears Say
Multi-year Revenue DeclineSustained top‑line contraction weakens operating leverage and undermines recurring consumables growth that normally follows installed base expansion. Persistent revenue declines make it harder to cover fixed costs, prolong dependence on balance sheet liquidity and slow reinvestment in commercialization.
Negative Operating And Free Cash FlowChronic negative operating and free cash flow means the business consumes balance sheet resources to fund operations. Even with large cash reserves today, continued negative cash generation risks future dilution, constrains investment cadence and limits ability to scale commercial programs sustainably.
SPL Concentration And Program ExitsHeavy reliance on a subset of SPL partners—plus program terminations and a material $4M headwind from the largest customer—creates revenue volatility and execution risk. Concentration reduces predictability of milestone/royalty flows and makes recoverable growth contingent on partner program success.
MaxCyte News
MXCT FAQ
What was MaxCyte (MXCT)’s price range in the past 12 months?
MaxCyte (MXCT) lowest stock price was $0.64 and its highest was $2.47 in the past 12 months.
What is MaxCyte (MXCT)’s market cap?
MaxCyte (MXCT)’s market cap is $90.12M.
When is MaxCyte (MXCT)’s upcoming earnings report date?
MaxCyte (MXCT)’s upcoming earnings report date is May 12, 2026 which is tomorrow.
How were MaxCyte (MXCT)’s earnings last quarter?
MaxCyte (MXCT) released its earnings results on Mar 24, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.076 by -$0.014.
Is MaxCyte (MXCT) overvalued?
According to Wall Street analysts MaxCyte (MXCT)’s price is currently Undervalued.
Does MaxCyte (MXCT) pay dividends?
MaxCyte (MXCT) does not currently pay dividends.
What is MaxCyte (MXCT)’s EPS estimate?
MaxCyte (MXCT)’s EPS estimate is -0.08.
How many shares outstanding does MaxCyte (MXCT) have?
MaxCyte (MXCT) has 106,861,430 shares outstanding.
What happened to MaxCyte (MXCT)’s price movement after its last earnings report?
MaxCyte (MXCT) reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.076. Following the earnings report the stock price went down -6.892%.
Which hedge fund is a major shareholder of MaxCyte (MXCT)?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (― Downside)
$4.50 (― Downside)
Hedge Fund Trend
Decreased
By 692.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.3K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-24.06%
Trailing 12-Months
Asset Growth
-15.44%
Trailing 12-Months
Company Description
MaxCyte (MXCT)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Earnings Call
Q4 2026
0:00 / 0:00
MXCT Stock 12 Month Forecast
Average Price Target
$4.50
Ownership Overview
2.02% Insiders
10.63% Mutual Funds
10.14% Other Institutional Investors
68.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---